Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could stem cells shield kidneys after severe injury?

NCT ID NCT06654193

Disease control Sponsor: Hope Biosciences LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether stem cells from donated fat tissue can prevent kidney injury from getting worse in people who have been severely hurt in accidents or burns. About 70 ICU patients will receive either stem cells or a placebo. The goal is to see if the treatment is safe and helps kidneys recover faster, reducing the need for dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs)
What this could lead to
If it works, this could point toward a treatment that prevents acute kidney injury from getting worse after severe trauma or burn, reducing the need for dialysis.
What could go wrong
This is an early Phase 1/2 trial with only 70 participants, so results are preliminary. Stem cell infusions carry risks like allergic reactions or infection, and the treatment may not improve kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Between 18 and 75 years old AND 2. Diagnosed with Modified KDIGO Stage 2 AKI within the first 10 days after injury AND 3. Admitted to Intensive Care Unit or Intermediate Medical Unit AND 4. Received at least 3 units of any blood product within 6 hours of admission for trauma OR 15% or greater burn area OR any electrical burn OR any crush injury AND 5. Expected to survive at least 24 hours after diagnosis of KDIGO Stage 2 AKI AND 6. Patient or patient's Legally Authorized Representative (LAR) has voluntarily signed the informed consent. Exclusion Criteria: Patients are ineligible if they meet ONE OR MORE of the following: 1. Incarcerated individuals 2. Pregnant and lactating females 3. TBI deemed non-survivable by the trauma or neurosurgery attending physician 4. Hemodynamically unstable and requiring vasopressors for blood pressure support (systolic blood pressure ≥90 mmHg) during the 30-minute period prior to investigational product (IP) thawing/preparation 5. Pre-existing chronic kidney disease or acute kidney failure. 6. Pre-existing chronic liver disease. 7. Known immunodeficiency or concurrent use of potentially immunosuppressive medications at doses likely to result in an immunosuppressed status. 8. Active malignancy. 9. Known allergy to dimethyl sulfoxide or human serum albumin. 10. No available intravenous access (peripheral or central) of at least 22-gauge needle that can be utilized exclusively for IP during the time of planned infusion. 11. Clinical condition that would be anticipated to deteriorate with IV administration of 250 ml of crystalloid. 12. Known Do Not Resuscitate (DNR) prior to randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35294, United States

  • University of California, San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

  • University of Texas Health Science Center at Houston (UTHealth Houston)

    RECRUITING

    Houston, Texas, 77479, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.